VA-REGULA-FORENSICS
8.6.2021 14:02:08 CEST | Business Wire | Press release
Permission.io, the digital advertising platform that lets online marketers reward users for interacting with ads, announces the integration with the Regula Document Reader SDK to cover the full know-your-customer (KYC) process. The partnership mitigates the risk of fraud and delivers a verified audience to advertisers.
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. With 28 years of experience, Regula is a trusted name to experts in both the private and public sectors worldwide. The company has the industry’s largest database of document templates and uses artificial intelligence to automatically determine document type and reveal the visual signs of fraud. Proprietary Face Matching and Liveness Detection technologies make Regula a one-stop solution for identity verification.
Permission.io is a digital advertising platform that enables consumers to earn rewards for interacting with advertisements. The company uses blockchain technology to allow advertisers to reward consumers with ASK, the platform’s native digital currency, for signing up, providing profile and preference data, engaging with video ads, referring friends, and other activities.
“Digital Advertising is ripe for a change,” said Charles Silver, CEO of Permission.io . “Big tech exploits user data, and click fraud is estimated to grow into an $87 billion business in 2021. The major platforms grade their own homework, so to speak, and advertisers are getting the short end of the stick. Too often, the ads they pay to deliver are not even being seen. Permission is bringing the change this industry needs by respecting user data and by delivering to advertisers superior targeting and better ROI on their considerable spend.”
“Financial technology needs the most secure protection from fraud, and we’re happy to share our expertise in document forensics with emerging industry leaders to ensure clear and reliable fraud detection while onboarding and asset management,” said Arif Mamedov, President of Regula Forensics Inc . “Our web and mobile products have been designed to meet the requirements of fintech and to be seamlessly integrable into any scenario and interface.”
Regula Document Reader SDK parses documents and extracts personal data, eliminating manual data input and minimizing mistakes. When it comes to data validation, Regula’s technology cross-checks the data obtained from MRZ, VIZ, and barcodes. The process of user identification is completed with face matching in seconds, while the personal data is secured by the internal Permission network. “We are very excited to add Regula's invaluable expertise to our promise to prevent identity fraud and deliver a delightful user experience,” Silver said.
About Regula Forensics:
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. Regula’s software product suite includes ID verification, facematching and liveness technologies for mobile applications and web-based solutions, to build a seamless on-premises digital identity and biometric verification workflow.
135 international borders are equipped with Regula hardware and software products. Regula is an official partner of the UN, Interpol, OSCE, IATA and ICAO. For more information, visit https://mobile.regulaforensics.com .
About Permission.io:
Permission.io is the leading platform for permission advertising for eCommerce. The company has created the ASK digital currency to enable individuals to securely grant permission and monetize their data on Permission.io and 3rd-party e-commerce platforms. Advertisers reward consumers with ASK for interacting with brands and content, building trust, and increasing ROI. To learn more, visit https://permission.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005012/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom